The Bladder That Broke His Kidneys Is the One Getting the New One
A spinal cord injury patient who has self-catheterized for fifteen years is about to receive the kidney his own bladder eventually destroyed, and neither his induction regimen nor his overactive-bladder drug has ever been studied in someone doing both at once.
Owen P., a 41-year-old high school woodworking instructor, has managed his bladder by clean intermittent catheterization every four hours since a motorcycle accident left him with a T10 spinal cord injury fifteen years ago — a routine so embedded in his day that he schedules his classes' shop breaks around it and has, by his own count, missed a scheduled catheterization only a handful of times in over a decade. That same neurogenic bladder, high-pressure and poorly compliant on urodynamics despite years of anticholinergic therapy, is what slowly destroyed his native kidneys through reflux nephropathy over the better part of that same decade, and he is now three days from receiving a deceased-donor transplant. He has no diabetes, no coronary disease, no history of pressure injuries or recurrent urosepsis that might have made him a marginal transplant candidate, and has been on the waiting list for two years without a single episode of graft-threatening illness in that time — genuinely well, on paper, for a man about to hand his new kidney to the same bladder that failed the last one.
Jayanth and colleagues' 2019 retrospective cohort of transplant recipients with an abnormal lower urinary tract found that clean intermittent catheterization carried an odds ratio of 5 for post-transplant infective complications compared with recipients using a normal bladder — a real, substantial increase, though the same study found three-year graft and overall patient survival statistically indistinguishable between the groups despite that gap in infection rate. Owen's own overactive-bladder drug, mirabegron, was chosen years before transplant was even on the horizon specifically because, unlike the anticholinergics it replaced, it doesn't meaningfully compete with calcineurin inhibitors for CYP3A4 metabolism — a genuine pharmacologic advantage the transplant team is about to inherit along with everything else already in his chart, and one that turns out to interact with a different drug altogether should his regimen ever need to change to something built on a completely different mechanism.
Pre-transplant planning, three days out
Standard induction, standard maintenance. The cohort data everyone keeps citing found a real rise in infections with CIC, but the same study found three-year graft and overall survival comparable to patients with a normal bladder — which tells me the infections, while real, were being managed successfully, not silently costing grafts.
If that same study had shown graft survival actually suffering in the CIC group, I'd be having a very different conversation. It didn't, and under-immunosuppressing him on the strength of an infection-rate finding that didn't translate into worse graft outcomes isn't a cautious choice, it's an unproven one.
An odds ratio of 5 for infective complications is not a rounding error, and I'd be careful reading 'graft survival was comparable' as proof the extra infections were costless — that same cohort also showed significantly more re-admissions in the abnormal-bladder group, which is its own real burden on him even if the graft ultimately survived it.
I'm not proposing we under-treat rejection risk broadly — I'm proposing basiliximab specifically, which is itself a standard, guideline-supported induction choice, not an experimental compromise. Choosing the lower end of an accepted range given a documented risk factor isn't the same thing as gambling with his graft.
Whatever the team decides on induction, keep him on mirabegron rather than switching back to an anticholinergic — it was chosen for a real reason, and nothing about today's conversation changes that reasoning.
What I want on the record for later: Engle and Fair's 2018 hematopoietic transplant case report found mirabegron raised sirolimus concentrations into the supratherapeutic range in another patient, almost certainly through a transporter interaction rather than the CYP3A4 pathway everyone checked for tacrolimus. If he's ever converted to an mTOR inhibitor for graft-related reasons down the road, that combination needs a level checked, not assumed safe by analogy to the tacrolimus data.
Agreed: basiliximab induction, tacrolimus-based maintenance at standard target troughs, and mirabegron continued unchanged. The infectious disease physician's concession that basiliximab is itself a standard, not experimental, induction choice is what actually closed the gap between the two positions — this wasn't a case of the nephrologist being talked out of adequate immunosuppression, but of finding a choice already inside accepted range that also answered the infection-risk concern.
Left explicitly open: whether a single retrospective cohort's infection-rate finding, without a matching graft-survival signal, should really have moved the induction choice at all. The nephrologist's original position was never fully retracted, only outvoted by a compromise everyone could accept — and the mirabegron-sirolimus interaction was filed as a flag for the future rather than a problem for today.